OncoMatch/Clinical Trials/NCT06922591
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Is NCT06922591 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for pdac.
Treatment: TNG462 · RMC-9805 · RMC-6236 · mFOLFIRINOX · gemcitabine/nab-paclitaxel — TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: MTAP loss of protein
Has a tumor with loss of MTAP protein
Required: MTAP bi-allelic deletion
bi-allelic deletion of the MTAP gene
Required: KRAS mutation
Arms A and B only: Has a tumor with a RAS mutation
Required: NRAS mutation
Arms A and B only: Has a tumor with a RAS mutation
Required: HRAS mutation
Arms A and B only: Has a tumor with a RAS mutation
Disease stage
Required: Stage IV, III
metastatic PDAC or locally advanced, recurrent or metastatic NSCLC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy
Has received prior standard therapy
Cannot have received: RAS-targeted therapy
Exception: Arms A and B only
Arms A and B only: Must not have received prior RAS-targeted therapy
Cannot have received: PRMT5 inhibitor
Has received prior treatment with a PRMT5 inhibitor
Cannot have received: MAT2A inhibitor
Has received prior treatment with a MAT2A inhibitor
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Scottsdale · Scottsdale, Arizona
- Sarah Cannon Research Institute Denver · Denver, Colorado
- Mayo Clinic Jacksonville · Jacksonville, Florida
- University of Indiana · Indianapolis, Indiana
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify